GCBRGCN: Integration of ceRNA and RGCN to Identify Gastric Cancer Biomarkers.
1/5 보강
Gastric cancer (GC) is a prevalent malignancy, and the discovery of biomarkers plays a crucial role in the diagnosis and prognosis of GC.
APA
Zhi P, Liu Y, et al. (2025). GCBRGCN: Integration of ceRNA and RGCN to Identify Gastric Cancer Biomarkers.. Bioengineering (Basel, Switzerland), 12(3). https://doi.org/10.3390/bioengineering12030255
MLA
Zhi P, et al.. "GCBRGCN: Integration of ceRNA and RGCN to Identify Gastric Cancer Biomarkers.." Bioengineering (Basel, Switzerland), vol. 12, no. 3, 2025.
PMID
40150719 ↗
Abstract 한글 요약
Gastric cancer (GC) is a prevalent malignancy, and the discovery of biomarkers plays a crucial role in the diagnosis and prognosis of GC. However, current strategies for identifying GC biomarkers often focus on a single ribonucleic acid (RNA) class, neglecting the potential for multiple RNA types to collectively serve as biomarkers with improved predictive capabilities. To bridge this gap, our study introduces the GC biomarker relation graph convolution neural network (GCBRGCN) model which integrates the competing endogenous RNA (ceRNA) network with GC clinical informations and whole transcriptomics data, leveraging the relational graph convolutional network (RGCN) to predict GC biomarkers. It demonstrates exceptional performance, surpassing traditional machine learning and graph neural network algorithms with an area under the curve (AUC) of 0.8172 in the task of predicting GC biomarkers. Our study identified three unreported potential novel GC biomarkers: CCNG1, CYP1B1, and CITED2. Moreover, FOXC1 and LINC00324 were characterized as biomarkers with significance in both prognosis and diagnosis. Our work offers a novel framework for GC biomarker identification, highlighting the critical role of multiple types RNA interaction in oncological research.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Raman Spectroscopic Signatures of Hepatic Carcinoma: Progress and Future Prospect.
- Nanotechnology-Assisted Molecular Profiling: Emerging Advances in Circulating Tumor DNA Detection.
- The role of disulfidptosis-driven tumor microenvironment remodeling in pancreatic cancer progression.
- SMURF2 in Anticancer Therapy: Dual Role in Carcinogenesis and Theranostics.